Silver Book Fact

The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about 25% when treated with the AREDS nutritional formula (daily, high-dose combination of vitamins C,E, beta-carotene, and zinc).

Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8. Arch Opthalmol. 2001; 119(10): 1417-36. http://archopht.jamanetwork.com/article.aspx?articleid=268224

Reference

Title
A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8
Publication
Arch Opthalmol
Publication Date
2001
Authors
Age-Related Eye Disease Study Research Group
Volume & Issue
Volume 119, Issue 10
Pages
1417-36
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • The ACCORD Eye Study found that intensive glycemia control–compared with standard blood sugar control–in high risk type 2 diabetics, decreased progression of diabetic retinopathy by around 1/3 over 4 years–from…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.  
  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…